The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / How Leukemia Develops Over Decades
Hematology Genetics and epigenetics Omics Screening and monitoring Research and Innovations Molecular Pathology

How Leukemia Develops Over Decades

Long-term tracking of blood mutations reveals how acute myeloid leukemia develops and identifies potential opportunities for earlier risk assessment

11/17/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: How Leukemia Develops Over Decades

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: How Leukemia Develops Over Decades
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPopulation described in the source article.
Care SettingResearch context: annual blood-sample analysis using TETRIS-seq to track mutations and mutated-cell populations; the findings do not establish a screening test.

Key Highlights

  • In approximately two-thirds of participants who developed AML, the first cancer-associated mutation was estimated to have appeared before age 20.
  • Mutated cell populations initially grew slowly, with growth accelerating as additional mutations accumulated.
  • Future AML cases showed more extensive expansion and competition between mutated cell populations than healthy controls.
  • UK Biobank analysis found that extensive expansion of a mutated cell population was associated with substantially increased odds of developing myeloid leukemia.
  • The study involved a relatively small cohort of older women, and approximately one-fifth of AML cases showed little detectable warning before diagnosis.

Guideline-Based Recommendations

Diagnosis

  • The study used TETRIS-seq to track AML-associated mutations and changes in the size of mutated blood-cell populations.
  • The authors suggest that molecular risk assessment could examine both which mutations are present and how extensively affected cells have expanded.

Management

  • The findings do not establish a screening test or a preventive intervention.

Monitoring & Follow-up

  • The authors state that further validation is needed to determine whether monitoring these genetic changes can reliably identify high-risk individuals and guide preventive intervention.

Risks

  • Approximately one-fifth of AML cases showed little detectable warning before diagnosis.
  • The study involved a relatively small cohort of older women.
  • Current sequencing pipelines may overlook some high-frequency acquired mutations because they resemble inherited variants.

Patient & Prescribing Data

No treatment or prescribing data are reported. The study analyzed annual blood samples from 47 women who later developed AML and 46 age-matched controls who remained free of blood cancer.

The article reports no treatment recommendations; it describes research into mutation patterns and potential risk assessment.

Clinical Best Practices

  • The study did not establish a screening test.
  • The study examined mutation presence and the extent of mutated-cell expansion.
  • Approximately one-fifth of AML cases showed little detectable warning before diagnosis.
  • The authors state that further validation is needed before determining whether monitoring these genetic changes can identify high-risk individuals and guide preventive intervention.

Related Resources & Content

  • Research published in Nature; article source URL not provided

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.